Objective: Myeloid cells, including macrophages and dendritic cells, are a prominent component of central nervous system (CNS) infiltrates during multiple sclerosis (MS) and the animal model experimental autoimmune encephalomyelitis (EAE). Although myeloid cells are generally thought to be proinflammatory, alternatively polarized subsets can serve noninflammatory and/or reparative functions. Here we investigate the heterogeneity and biological properties of myeloid cells during central nervous system autoimmunity. Methods: Myeloid cell phenotypes in chronic active MS lesions were analyzed by immunohistochemistry. In addition, immune cells were isolated from the CNS during exacerbations and remissions of EAE and characterized by flow cytometric, genetic, and functional assays. Results: Myeloid cells expressing inducible nitric oxide synthase (iNOS), indicative of a proinflammatory phenotype, were detected in the actively demyelinating rim of chronic active MS lesions, whereas macrophages expressing mannose receptor (CD206), a marker of alternatively polarized human myeloid cells, were enriched in the quiescent lesion core. During EAE, CNS-infiltrating myeloid cells, as well as microglia, shifted from expression of proinflammatory markers to expression of noninflammatory markers immediately prior to clinical remissions. Murine CNS myeloid cells expressing the alternative lineage marker arginase-1 (Arg1) were partially derived from iNOS 1 precursors and were deficient in activating encephalitogenic T cells compared with their Arg1 2 counterparts. Interpretation: These observations demonstrate the heterogeneity of CNS myeloid cells, their evolution during the course of autoimmune demyelinating disease, and their plasticity on the single cell level. Future therapeutic strategies for disease modification in individuals with MS may be focused on accelerating the transition of CNS myeloid cells from a proinflammatory to a noninflammatory phenotype.
M yeloid cells, including macrophages (MFs) and dendritic cells (DCs), are a major component of white matter lesions in multiple sclerosis (MS) and the animal model experimental autoimmune encephalomyelitis (EAE).
1,2 Our laboratory and others have established a critical role of myeloid cells in early EAE pathogenesis. [3] [4] [5] [6] Myeloid cells may serve as antigen-presenting cells for reactivation of myelin-specific CD4 1 T cells, 7, 8 secrete cytokines such as IL-6, IL-1b, and TNFa, 9 and directly inflict damage through release of toxic factors such as reactive oxygen species generated by inducible nitric oxide synthase (iNOS). 10, 11 iNOS-expressing myeloid cells are often described as classically activated, and considered "proinflammatory," based on their similarity to bone marrow-derived macrophages (BMDMs) that were polarized with lipopolysaccharide or interferon-c (IFNc) in vitro. 12 It is generally thought that classically activated myeloid cells (CAMCs) are predominant in active MS and EAE lesions, where they act as pathogenic effector cells. [13] [14] [15] Early studies of autopsied MS brains revealed iNOS-immunoreactive macrophages in active lesions. 14, 16, 17 The presence of iNOS 1 myeloid cells generally correlated with zones of ongoing demyelination. However, there is growing evidence that myeloid cells that accumulate in the central nervous system (CNS) are heterogeneous and likely encompass a spectrum of lineages with diverse, and even opposing, properties. [18] [19] [20] In contrast to iNOS, the enzyme arginase-1 (Arg1) and the mannose receptor (CD206) have been identified as markers of myeloid cells with "immunosuppressive" or "proregenerative" properties. Arg1/CD206-expressing myeloid cells play a critical role in wound healing. 21 They are frequently classified as alternatively activated based on their similarity to BMDMs generated in vitro by polarization with IL-4 or IL-13 via a STAT6-dependent pathway. 12, 22 Alternatively activated myeloid cells (AAMCs) may regulate the inflammatory environment by secreting IL-10 and/or TGFb1, 9 while promoting tissue regeneration by clearing debris 23, 24 and secreting growth factors. 25 Foamy (lipidladen) macrophages, perivascular macrophages, and microglia expressing human AAMC markers, such as CD206 and CD163, have been discovered in acute and chronic active MS lesions. 2, 19, 25, 26 Primary human macrophages acquire a foamy morphology and produce immunosuppressive factors following ingestion of myelin in vitro. 19 We questioned whether CNS myeloid cells evolve during disease progression and shift from a proinflammatory phenotype at onset to a noninflammatory or immunosuppressive state in anticipation of clinical remission/ stabilization. Consistent with this hypothesis, CNSinfiltrating DCs were found to upregulate the AAMCassociated genes Arg1, Chi3l3, and Ms4a8a at the peak of EAE, shortly prior to remission. 27 Arg1 is the most significantly upregulated gene in the CNS at peak EAE. 28 Adoptive transfer of AAMC-polarized macrophages or microglia can ameliorate EAE, 29, 30 and the therapeutic effects of estrogen, glatiramer acetate, and other agents in EAE were found to correlate with the expansion of AAMCs in the periphery and/or CNS. [31] [32] [33] [34] Less is known about endogenous AAMCs that spontaneously accumulate in the CNS during the course of EAE or MS. In the current paper, we compare the spatial distribution of AAMCs in actively demyelinating and quiescent regions of MS lesions. In addition, we examine the origin, kinetics, and biological properties of CNS myeloid subsets from the preclinical stage of EAE through peak and remission.
Materials and Methods

Mice
C57Bl/6 and B6.Ly5.1 mice were from Charles River Laboratories (Wilmington, MA). Arg1-eYFP, 35 Rosa-LSL-eYFP, 2D2
TCR transgenic, and STAT6 2/2 mice were from Jackson Laboratory (Bar Harbor, ME). iNOS-TdTomato-Cre 36 mice were from the European Mouse Mutant Archive (INFRAFRONT-IER, Neuherberg/Munich, Germany). SJL mice were from Harlan Laboratories (Horst, the Netherlands). Both male and female mice, age 6 to 12 weeks, were used in experiments. All mice were bred and maintained under specific pathogen-free conditions at the University of Michigan, and all animal experiments were performed in accordance with an institutional animal care and use committee-approved protocol at the University of Michigan.
Induction and Assessment of EAE
For active immunization, C57Bl/6 mice were subcutaneously immunized over the flanks with 100 mg MOG 35- 
Cell Isolation
Mice were anesthetized with isoflurane. Mice were perfused with phosphate-buffered saline (PBS) through the left ventricle. Draining lymph nodes and spleens were isolated, and a singlecell suspension was generated by passing cells through a 70 mm mesh filter. For collection of CNS mononuclear cells, brains were dissected from the skull, and spinal cords were flushed from the spinal column with PBS. Tissues were homogenized with an 18Ga needle and syringe in a solution containing 1mg/ ml collagenase A (Roche, Basel, Switzerland) and 1mg/ 
Quantitative Real-Time Polymerase Chain Reaction
Sorted cells were resuspended in RLT buffer, and RNA was isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was generated by reverse transcription with the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed on an iQ Thermocycler (Bio-Rad Laboratories, Hercules, CA) using the iQ SYBR Green Supermix. Relative gene expression was determined with the DCT method with normalization to Actb.
Ex Vivo Cultures
For purification of naive CD4 1 T cells, lymph nodes and spleen were collected from naive 2D2 TCR transgenic mice, and CD4 1 T cells were enriched by positive selection with magnetic beads (Miltenyi Biotec). To further isolate naive T cells, cells were sorted for live CD4
For purification of memory T cells, mononuclear cells from the CNS were flow sorted for live CD45 
Multiplex Immunoassays
Cell culture supernatants were analyzed with the Milliplex Mouse Th17 Cytokine Panel (EMD Millipore, Billerica, MA) using the Bio-Plex 200 System (Bio-Rad Laboratories). Values below the reported level of detection of the assay (minDC) were assigned a value of 0.5*minDC for statistical analysis and represented on graphs as not detectable.
Immunohistochemistry on MS Brain Tissue
Human CNS tissue was obtained at autopsy according to an institutional review board-approved protocol at Yale University. CNS tissue was obtained from 4 subjects with MS, and a total of 5 chronic active white matter lesions were examined. Lesions were identified as "chronic active" according to the classification proposed by Bruce Trapp. 37 Specifically, lesions were characterized by ongoing demyelination at the lesion rim, with dense infiltration of CD68-positive myeloid cells that contained myelin degradation products. 
Statistics
Statistical analysis was performed using paired or unpaired, 2-tailed Student t test, as indicated in the figure legends.
Results
Macrophage Polarization Shifts from the Core to the Rim of MS Lesions
To characterize the polarization state of CD68 1 macrophage in chronic active MS lesions, we immunolabeled brain tissue sections from 4 patients ( Table) with antibodies against iNOS and CD206, the standard markers of classically and alternatively activated human myeloid cells, respectively. 2, 14, 38, 39 MS lesions tend to grow centrifugally over time, with inflammatory activity gradually moving outward. Chronic active lesions have a relatively quiescent and hypocellular lesion center, due to waning of the earlier inflammatory response, surrounded by a rim of macrophages with early myelin degradation products, signifying ongoing demyelination. 37 We found that a high percentage of CD68 1 macrophages at the lesion rim were iNOS 1 , whereas relatively few macrophages expressed CD206 (see Fig 1A-D) . Conversely, the percentage of CD206 1 cells was higher than iNOS 1 cells among those macrophages in the center of the lesion. We detected iNOS/CD206 double-positive macrophages in all 5 MS lesions, which were most numerous in the lesion center (see Fig 1E) . Consistent with our results, Vogel and colleagues discovered foamy macrophages and activated microglia in a panel of active MS lesions that consistently coexpressed AAMC and CAMC markers. Arg1 Is Expressed by a Subset of CNS-Infiltrating Myeloid Cells at Peak EAE Next, we investigated the phenotypes of CNS myeloid cells during the course of EAE. We found that the myeloid cells that accumulate in the CNS do not convincingly express CD206 at onset, peak, or late time points of EAE, but a subset of splenic myeloid cells inconsistently expressed CD206 at high levels (data not shown). Because Arg1 is commonly used to identify murine AAMCs, 12 we measured expression of iNOS and Arg1 at serial time points following active immunization with myelin peptide. We detected iNOS, but not Arg1, in mononuclear cells isolated from the brain or spinal cord at clinical onset (Fig  2A) . In contrast, at peak disease we detected Arg1, but not iNOS, in the CNS mononuclear cells. CAMC-related genes (iNOS, IL-1b, IL-6) were unchanged or reduced (see Fig 2C) . Fig 2D) . Nonetheless, the accumulation of Arg1 1 CNS myeloid cells was largely preserved in the absence of STAT6. Fig 3B) . Next, we used a relapsing-remitting model of EAE in SJL mice to determine whether myeloid cells undergo cyclical shifts in iNOS and Arg1 expression through multiple relapses. We observed that an iNOS 1
Myeloid Cells Shift from iNOS to Arg1 Expression during the Evolution of Adoptively
Arg1
2 subset had accumulated by the onset of the first exacerbation, contracted during peak disease through remission, and rebounded at the onset of relapse (see Fig 3C-E) . In contrast, an iNOS 2 Arg1 1 subset expanded between clinical onset and peak of the first episode of EAE, waned during remission, and reemerged at the peak of relapse.
Collectively, these results demonstrate that a shift in myeloid cell phenotype parallels clinical exacerbations and remissions/plateaus and is consistent across multiple models of EAE.
Individual Myeloid Cells Convert from iNOS to Arg1 Expression Zhu and colleagues described immunosuppressive Ly6C hi monocytes that expand in the periphery, accumulate in the CNS during EAE, and have the potential to differentiate into either iNOS 1 or Arg1 1 cells upon ex vivo culture with different polarizing factors. 20 As shown in Figures 1 and 3 ; Fig 4A,  B) . At this point, iNOS protein is no longer detectable (see Fig 4B) . Approximately 45% of the iNOS FM1 subset coexpressed Arg1 (see Fig 4C) , demonstrating that individual CNS-infiltrating myeloid cells are capable of transitioning from expression of iNOS to expression of Arg1 during the course of disease. However, Arg1 expression is not absolutely dependent on prior expression of iNOS, because 15% of the iNOS FM2 cells were also Arg1
1
. Notably, a higher percentage of Arg1 1 than Arg1 2 cells were derived from iNOS FM1 precursors (33% vs 9%). These data demonstrate that Arg1-expressing cells may be derived either from iNOSexpressing cells or from iNOS-naive cells.
Arg1-Expressing CNS Myeloid Cells Are Inefficient Antigen-Presenting Cells
DCs have been identified as potent antigen-presenting cells in the CNS during EAE. 7, 42 We sought to compare the antigen-presenting cell function of Arg1 1 versus Arg1 2 CNS DCs by measuring the ability of each subset to promote myelin-specific T-cell proliferation ex vivo.
Sorted CNS DC subsets were cocultured with naive 2D2 CD4 1 T cells, which bear a transgenic T-cell receptor specific for myelin oligodendrocyte glycoprotein peptide (MOG ), in the presence of myelin peptide. Compared with their Arg1 2 counterparts, Arg1 1 CNS DCs were inefficient in promoting the proliferation of, or cytokine production by, myelin-specific T cells (Fig 5A,  B) . Similar results were obtained when MOG protein was used as the recall antigen (data not shown). 
Discussion
Collectively, the data presented in our study demonstrate the heterogeneity and plasticity of myeloid cells within the CNS in MS and EAE. We identified an Arg1 1 CNS myeloid population during the peak and later stages of EAE that is deficient in the capacity to activate myelinspecific T cells. The appearance of Arg1 1 myeloid cells cells in MS lesions also coexpress CAMC and AAMC markers raises the possibility that they undergo a dynamic transformation from a proinflammatory to a noninflammatory state. Such a transformation is further suggested by the increasing gradient of iNOS versus CD206 expression in macrophages extending from the quiescent center to the active rim of chronic active MS lesions. Second generation disease-modifying therapies (DMTs) in MS suppress clinical exacerbations by depleting peripheral lymphocytes or blocking their trafficking to the CNS. Although these reagents are highly effective in many individuals with relapsing-remitting MS, they are not cures, with up to 30% nonresponse rates. Furthermore, DMTs currently used in the clinic are generally ineffective in progressive forms of MS. Myeloid cells and related factors have been underutilized as candidate therapeutic targets in MS clinical trials. This is particularly relevant to secondary progressive MS, because numerous studies point to dysregulation of the innate arm of the immune system and, in particular, cells of the myeloid lineage as a distinctive feature of that stage of disease. [47] [48] [49] [50] The current findings suggest an opportunity for slowing, or even halting, progressive disability in patients with MS via the development of novel therapeutics that suppress pathogenic myeloid subsets in a targeted manner and/or promote their conversion to a noninflammatory phenotype.
